Estrella Immunopharma (NASDAQ:ESLA) Earns Buy Rating from Analysts at D. Boral Capital

D. Boral Capital assumed coverage on shares of Estrella Immunopharma (NASDAQ:ESLA) in a research note issued to investors on Tuesday morning,Benzinga reports. The firm issued a buy rating and a $16.00 target price on the stock.

Estrella Immunopharma Trading Up 8.8 %

Shares of Estrella Immunopharma stock opened at $1.49 on Tuesday. The business’s fifty day simple moving average is $1.17 and its 200 day simple moving average is $1.10. Estrella Immunopharma has a 12 month low of $0.63 and a 12 month high of $3.23. The firm has a market capitalization of $53.91 million, a P/E ratio of -5.73 and a beta of 0.41.

Hedge Funds Weigh In On Estrella Immunopharma

A hedge fund recently raised its stake in Estrella Immunopharma stock. Geode Capital Management LLC boosted its stake in Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 22.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 93,418 shares of the company’s stock after acquiring an additional 16,862 shares during the period. Geode Capital Management LLC owned 0.26% of Estrella Immunopharma worth $106,000 as of its most recent filing with the SEC. 0.35% of the stock is currently owned by institutional investors and hedge funds.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.